New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
09:18 EDTSNE, MM, BMY, ISIS, RUBI, GSK, PTX, TTWO, CSIQ, FOSL, SODA, PLUG, CLDX, P, ENZYOn The Fly: Pre-market Movers
HIGHER: Pernix Therapeutics (PTX), up 42% after acquiring TREXIMET tablets for migraine from GlaxoSmithKline (GSK)... Isis Pharmaceuticals (ISIS), up 9.6% after Phase 2 results for ISIS-GCGR for diabetes reported... Canadian Solar (CSIQ), up 1.7% after partnering with Ikea to build 3.6MW solar systems... Pandora (P), up 1.4% following upgrade at Raymond James... Rubicon Project (RUBI), up 22% after upgraded at Oppenheimer and RBC Capital following its Q1 earnings report... Celldex (CLDX), up 10.5% after announcing collaboration agreement with Bristol-Myers (BMY)... Millennial Media (MM), up 3.4% after CEO Barrett purchases 291K shares. LOWER: Sony (SNE), down 5.6% after reporting FY13 results, guiding to losses in FY14... DOWN AFTER EARNINGS: Fossil (FOSL), down 6.5%... Enzymotec (ENZY), down 8.6%... Plug Power (PLUG), down 6.6%... SodaStream (SODA), down 3.2%... Take-Two (TTWO), down 3.5%.
News For SNE;P;CLDX;PLUG;SODA;FOSL;CSIQ;TTWO;PTX;GSK;RUBI;ISIS;BMY;MM;ENZY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
October 15, 2014
05:44 EDTCSIQCanadian Solar to power key solar projects in Honduras
Subscribe for More Information
October 14, 2014
17:15 EDTCSIQClaren Road Asset reports 5.83% passive stake in Canadian Solar
13:09 EDTGSKGlaxoSmithKline seeks binding bids for mature drugs, Reuters reports
Subscribe for More Information
11:23 EDTBMY, GSKBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:21 EDTFOSLFossil initiated with a Buy at Standpoint Research
Target $124.
11:19 EDTGSKNIH says several potential Ebola treatments under development
Subscribe for More Information
10:10 EDTGSKNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
06:42 EDTCSIQPV modules with solar-grade wafers to account for 89% of capacity, DigiTimes says
Solarbuzz says solar photovoltaic modules using solar-grade wafers will account for 89% of solar capacity forecast to be installed in 2014, reports DigiTimes. Thin-filmed panel makers will supply nearly 8% of end-market demand in 2014, while premium cyrstalline silicon suppliers making up the remaining 3% share. Publicly traded companies in the space include Canadian Solar (CSIQ), First Solar (FSLR), JA Solar (JASO), SunPower (SPWR), Trina Solar (TSL), Panasonic (PCRFY) and Yingli Green Energy (YGE). Reference Link
06:31 EDTPTXPernix Therapeutics management to meet with Needham
Subscribe for More Information
October 13, 2014
08:05 EDTBMYBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:22 EDTSNE, PSony/ATV could ditch licensing firms due to streaming dollars, NY Post reports
Sony/ATV Music Publishing (SNE) is considering no longer dealing with performance rights groups BMI and ASCP, and instead negotiating directly with online music services like Pandora (P), YouTube (GOOG) and Spotify due to outdated rules and low royalties, the New York Post reports. Reference Link
07:13 EDTBMYBioFlorida to hold a conference
Subscribe for More Information
07:12 EDTISIS, GSKOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
05:34 EDTCSIQCanadian Solar reports sale of 24.3 MWp of modules to EDF Renewable Energy
Subscribe for More Information
October 10, 2014
10:03 EDTBMYBristol-Myers receives orphan status for melanoma treatment
Subscribe for More Information
09:00 EDTISISOn The Fly: Pre-market Movers
Subscribe for More Information
08:19 EDTBMYMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
07:04 EDTSNEAmazon in talks to join digital locker for movies. WSJ reports
Subscribe for More Information
07:03 EDTPLUGPlug Power backs FY14 revenue guidance of $75M, consensus $75.93M
Subscribe for More Information
05:22 EDTISISIsis Pharmaceuticals reports data from ISIS-SMN Rx Phase 2 study
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use